"We're painting a pretty good picture for quality of life after our treatment for ICH," Hanley says.
Even patients who were initially more severely disabled continued to improve months after treatment, with the majority scoring lower on disability assessments after six months compared to the same assessments taken at 30 days. Another 40 percent had only mild to moderate disability and were independently caring for themselves at home by 180 days, but required assistance with everyday tasks such as lifting heavy objects. The researchers found that about 10 percent of patients had no lingering disability after six months. In the new study, the researchers report on the patients' progress six months after treatment using assessments for overall levels of disability as well as their skill in accomplishing specific tasks often affected by stroke, such as dressing, bathing or walking. However, since tPA is effective at breaking up clots in other conditions, such as heart attacks and other types of strokes, Hanley and his colleagues have been studying its safety and efficacy for treating ICH.Įarly results from this study using information collected 30 days after tPA treatment showed that about 80 percent survived, compared to data from previous studies showing that about 80 percent of untreated ICH patients die.
This drug normally isn't recommended for conditions that involve bleeding, such as ICH, because it can increase the risk of further hemorrhage. The treatment, developed by Hanley's team, gives low doses of tPA over several days after strokes involving intracerebral hemorrhage. The researchers worked with patients at 38 study sites scattered throughout the United States, as well as in Canada, Germany and Finland. Last May, study leader Daniel Hanley, M.D., professor of neurology at the Johns Hopkins School of Medicine, and his colleagues reported early findings among 52 intracerebral hemorrhage (ICH) patients treated with tPA given by catheter directly into patients' brains to bathe and destroy blood clots with this clot-busting agent.
#CLOT BUSTER ACTIVATOR#
19, are likely to build support for the use of tissue plasminogen activator (tPA) in patients with intracerebral hemorrhage, a treatment-resistant form of stroke marked by brain bleeding.
The findings, announced at the International Stroke Conference in San Diego on Feb. February 19, 2009- New results from a multicenter study led by Johns Hopkins show that patients who got an experimental clot-busting treatment for a particularly lethal form of stroke were not only dramatically more likely to survive but also continued to shed lingering disabilities six months later.
0 kommentar(er)
